Parkinson’s growth
October 5, 2011
WITH over 300 late-stage trials
for Parkinson’s disease drugs in
process, the market for Parkinson’s
drugs will reach US$3.7b in 2015,
according to a Visiongain report.
“Parkinson’s remains the most
treatable of the neurodegenerative
diseases, but the industry needs a
new approach to supplement
dopaminergic therapies,” said a
Visiongain analyst.
“In coming years, adenosine
receptor antagonists will boost the
Parkinson’s treatment armoury,
offering a way to bypass the
dopamine system and restore
damaged communicational links in
the brain,” the analyst added.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Oct 11To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Oct 11